At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
Vitamin D3 +1 moredrug
Likely dose
Vitamin D3 4,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
In Brief
A clinical study evaluating Vitamin D3 and placebo and vitamin D for Melanoma, Skin. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral vitamin D could be explored further as a chemoprevention for melanoma skin cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Skin
CountriesUnited States
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartSep 2012
Primary CompletionMay 2014
TodayJul 2026
First PostedNov 22, 2011
Enrollment StartSep 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.6 years ago
Interventions
Vitamin D3drug
4,000 IU oral vitamin D3
placebo and vitamin Ddrug